TickerFacts.

Longeveron Inc. (LGVN): Shareholders' Equity

Annual figures by period end, from SEC filings.

$5.67M
As of 2025-12-31
$10.40M
As of 2026-06-30
-34.8%
3-year compound annual growth
+23.7%
5-year compound annual growth
$37.45M2020-12-31: $1.96M2021-12-31: $37.45M2022-12-31: $20.50M2023-12-31: $6.74M2024-12-31: $21.89M2025-12-31: $5.67M$5.67M
2020-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$5.67M-74.1%2026-03-17, Balance as of period end
2024-12-31$21.89M+224.7%2026-03-17, Balance as of period end
2023-12-31$6.74M-67.1%2025-02-28, Balance as of period end
2022-12-31$20.50M-45.3%2024-02-27, Balance as of period end
2021-12-31$37.45Mn/m2023-03-14, Balance as of period end
2020-12-31$1.96Mn/a2022-03-11, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Longeveron Inc. (LGVN)2025-12-31$5.67M-74.1%
Neuphoria Therapeutics Inc. (NEUP)2026-06-30$24.60M+29.5%
China SXT Pharmaceuticals, Inc. (SXTC)2026-03-31$29.71M+92.4%
Vistagen Therapeutics, Inc. (VTGN)2026-03-31$35.52M-49.5%
IGC Pharma, Inc. (IGC)2025-03-31$6.33M-13.5%
Bespoke Extracts, Inc. (BSPK)2024-12-31-$2.09Mn/m
Cannapharmarx, Inc. (CPMD)2025-12-31-$30.15Mn/m
Northwest Biotherapeutics Inc (NWBO)2025-12-31-$60.28Mn/m
Dare Bioscience, Inc. (DARE)2025-12-31$2.84Mn/m

Compare LGVN, NEUP, SXTC, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗